Remove Bioassay Remove Development Remove Gene Remove In-Vivo
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E.

article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

Drug discovery and development is an arduous process that can cost upwards of $2.6 Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. billion and take over 10 years.